Navigation Links
Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 10th Annual BIO CEO and Investor Conference on Tuesday, February 12, 2008 at 2:45 p.m. EST (11:45 p.m. PST). The conference is being held at the Waldorf-Astoria Hotel in New York.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc., will present an overview of Anadys and its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through February 26, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines in the areas of hepatitis C and cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and the "Risk Factors" section of Anadys' Form 10-Q for the quarter ended September 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant ... officially launched and multiple surgeries have been completed with this new posterior thoracolumbar ... Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal System pioneers ...
(Date:10/9/2015)... 9, 2015 Governor Tom Wolf ... company focused on developing T-cell receptor cancer immunotherapy treatments, ... a new expansion project. Pennsylvania ... commonwealth as 110 new, high-paying jobs will be created ... "My budget proposal includes sustained funding for the life ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to food to ... cells from their surroundings for research, diagnostics, and cell therapy—also known as cell ... Ann Arbor-based startup Akadeum Life Sciences is developing a radically new ...
(Date:10/8/2015)... Oct. 8, 2015  Sorrento Therapeutics, Inc. (NASDAQ: ... treatments for cancer and associated pain, announced today that ... be presenting at the Aegis Capital Corporation 2015 ... :Event:Aegis Capital Corporation 2015 Growth ConferenceDate:Friday, October 9, ... Encore @ The Wynn in Las Vegas, NV ...
Breaking Biology Technology:
(Date:9/28/2015)... 28, 2015 Synaptics Inc. (NASDAQ: SYNA ... announced that Lenovo has selected Synaptics , Natural ... its latest smartphone, the Vibe P1. The new ... the device and provide swift access to applications and ... Natural ID FS4202 sensor solution utilizes AES256-bit encryption of ...
(Date:9/24/2015)... 2015  EyeLock LLC, a market leader of iris-based ... and latest technology in Booth #602 at next week,s ... EyeLock,s iris authentication technology provides an unprecedented ... making it the most proven way to authenticate one,s ... to deliver a fast and friendly user experience to ...
(Date:9/10/2015)... 2015 This report provides detailed descriptions of ... and emerging sensor types that will dominate in the ... of the wearable technology hype curve in the last ... common feature with all of them is the prominence ... most useful functions. Sensors collect data about the physical ...
Breaking Biology News(10 mins):